Regeneron’s Pasatru wins FDA approval in ultra-rare ‘stone man disease’
RegulatoryapprovedPasatruPositive
AI Analysis
Summary
Regeneron's Pasatru received FDA approval for ultra-rare 'stone man disease' following Phase III trial demonstration of strong efficacy in reducing lesions and flare-ups.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
FDA approval for ultra-rare 'stone man disease'
Importance:8/10
Sentiment:
0.90
FDA approvalrare diseasePhase IIIRegeneron
Related Companies
Read the original article
Published by Pharmaceutical Technology on August 20, 2026 10:39 AM